Total trials
97
Active
10
Phase 3
5
Total enrollment
9,256
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Silver diamine Fluoride 38% | — | — | — | — | — | 1 | |
| Cefazolin | — | — | — | — | — | 1 | |
| Ceftriaxone | — | — | — | — | — | 1 |
Next readouts
- 2026-11-15
- 2026-12
Top conditions
- Stroke4
- Pain4
- Asthma3
- Obstructive Sleep Apnea3
- Exercise3
- Child Development Disorders, Pervasive2
- Patient Simulation2
- Intubation; Difficult or Failed2
Frequently asked questions about Université de Montréal
- How many clinical trials does Université de Montréal have on ClinicalTrials.gov?
- Université de Montréal is listed as the lead sponsor on 97 clinical trials in ClinicalTrials.gov, 10 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Université de Montréal's trials are in Phase 3?
- 5 of Université de Montréal's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Université de Montréal focus on?
- Université de Montréal's most-studied conditions on ClinicalTrials.gov are Stroke, Pain, Asthma, Obstructive Sleep Apnea, Exercise.
- When are Université de Montréal's next clinical trial readouts?
- Université de Montréal has 2 upcoming primary-completion readouts tracked here; the soonest is “Pilot and Feasibility Study of Impact of SDF 38% Application on Oral Health of Elderly With Autonomy Loss”, expected around 2026-11-15.